|
| |
ActivBioticsMISSIONActivBiotics is focused on the development and commercialization of antibacterials for the treatment of acute and chronic disease.
PRODUCT PORTFOLIO
ActivBiotics is developing rifalazil - a potent broad spectrum antibiotic that targets and inhibits the transcriptional machinery of bacteria. Previously studied in Phase I and IIA clinical trials, rifalazil is currently being planned for additional Phase II trials in several indications. In addition, ActivBiotics is owns a proprietary library of structurally related new chemical entities (NCEs).
| Contact Details: |
| 2 Oliver Street, 3rd Floor |
| Boston |
| MA |
| 02109 |
| United States of America |
| Tel: | (617) 423 9995 |
| Fax: | (617) 423 9997 |
| Email: | info@activbiotics.com |
| WWW: | www.activbiotics.com/
|
|
Loading...
|
Recent Publications by ActivBiotics: |  |
Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae.
Rifampin-resistant mutants of the obligate intracellular pathogen... | 20th December, 2008
| ActivBiotics,
| J Antibiot (Tokyo). 2008 Aug;61(8):489-95.
DOI Direct Link |
Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization.
The rifamycin rifalazil (RFZ), and derivatives (NCEs) were efficacious in... | 20th December, 2008
| ActivBiotics, Inc,
| J Antibiot (Tokyo). 2008 Aug;61(8):485-8.
DOI Direct Link |
Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters.
PURPOSE: M40403 is a small-molecule superoxide dismutase mimetic that has... | 1st August, 2008
| ActivBiotics, Inc., Lexington, Massachusetts, USA.
| Clin Cancer Res. 2008 Jul 1;14(13):4292-7.
DOI Direct Link |
Determination of rifalazil in dog plasma by liquid-liquid extraction and LC-MS/MS: quality assessment by incurred sample analysis.
Incurred dog plasma samples were utilized for method quality assessment in... | 4th March, 2008
| ActivBiotics, Inc., 110 Hartwell Avenue, Lexington, MA 02421, USA.
| J Pharm Biomed Anal. 2007 Nov 30;45(4):616-24. Epub 2007 Sep 12.
DOI Direct Link |
Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections.
Rifalazil is a benzoxazinorifamycin which inhibits bacterial DNA-dependent... | 6th February, 2008
| ActivBiotics, Inc., Lexington, Massachusetts 02421, USA.
| Arch Pharm (Weinheim). 2007 Oct;340(10):517-29.
DOI Direct Link |
→View more ActivBiotics research publications. |
Press Releases on ActivBiotics:
|
 |
| Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc., Releases Statement Regarding Liquidation Process |
22nd October, 2009 |
Joseph F. Finn, Jr., C.P.A. |
WELLESLEY HILLS, Mass., Oct. 22 /PRNewswire/ -- The previously announced auction of assets of EPIX Pharmaceuticals, Inc. was conducted on October 21, 2009. As of today, claims filed against the
|
| Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009 |
1st October, 2009 |
Joseph F. Finn, Jr., C.P.A. |
WELLESLEY HILLS, Mass., Oct. 1 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there was a successful auction sale of five drug program intellectual properties on
|
| EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction |
1st September, 2009 |
Joseph F. Finn, Jr., C.P.A. |
WELLESLEY HILLS, Mass., Sept. 1 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the
|
| EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction |
25th August, 2009 |
|
WELLESLEY HILLS, Massachusetts, August 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023
Therapeutics Program in Phase 2b/3 will be part of the
|
| Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers |
22nd June, 2009 |
Joseph F. Finn, Jr., C.P.A. |
WELLESLEY HILLS, Mass., June 22 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 660 times since April 2007, the link to the organisation's website has been followed 154 times Recent Search Terms used to find this page: activ bioti | activ bioti | activbiotics careers | activ bio | activbiotics | activbiotics pharma | activbiotics 2009 | activbiotics homepage 2009 | rifalazil sale | ActivBiotics | . Search for more companies in Boston Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for ActivBiotics |
